Preparing a healthier tomorrow

Hereditary Cancer Syndrome is hereditary syndrome in which defects in cancer predisposing gene is
inherited to next generation and accounts for 10% of all cancer incidences.¹
If there are defects in cancer disposing genes. Risk of cancer incident is greatly increased and chance of
early onset is also increased.²
Testing for Cancer predisposing genes allows screening of high-risk group to allow for proper medical
management allowing for increased cancer prevention effect and improved treatment.

개요 이미지

What is a heredicancer discovery ?

Recognition can lead to Prevention

heredicancer discoverytest for cancer predisposing genes associated with different cancers using
NGS (next generation sequencing) and has been developed with major hospitals in Korea on a national grant.

The tested genes in heredicancer discovery mainly consists of well document high risk genes
with known management guidelines.³ It is important that whole gene needs to be tested, rather than certain regions,
because cancer inducing variants dispersed over the gene. Unlike some tests which look for variants in certain regions,
heredicancer discoverychecks the whole gene, allowing for more accurate variant detection and thus providing
a better medical diagnostic utility.

heredicancerDiscovery란 이미지

Detectable Diseases

With just one test, almost every hereditary cancer risk can be tested

is testing the following types of cancer that can be caused by genetic factors :

  • 유방암

    Breast Cancer

  • 난소암

    Ovarian Cancer

  • 자궁내막암


  • 췌장암


  • 대장암

    Colon Cancer

  • 소장암

    Small Bowel

  • 뇌암

    Brain Cancer

  • 전립선암

    Prostate Cancer

  • 신장 & 요로암

    Kidney & Urinary
    Tract Cancer

  • 부신암


  • 쓸개암

    Liver Cancer

  • 위암

    Stomach Cancer

  • 폐암

    Lung Cancer

  • 혈액암

    Blood Cancer

  • 갑상선암

    Thyroid cancer

  • 육종


  • 피부암

    Cutaneous cancer

To whom is this useful to?

Know your risk 검사대상 이미지
  • Anyone whose family member has cancer incidence of the same type
  • Anyone whose family member has early-onset cancer
  • Anyone whose family member has multiple primary cancer incidence
  • Anyone whose family member has multiple primary cancer incidence in the same organs (ex bilateral breast cancer)
  • Anyone whose family member has rare cancer incidence
  • Anyone who would like to know their risk of cancer and would like to manage the risk.

Test Procedure

SD Genomics is a reliable genetic testing service company

SD Genomics performs genetic tests to the requests of medical institutes following the Bioethics and Safety Act. Prior to service request,
understanding the objective of the test, reporting method of the test, and limitations of the test is necessary.

검사절차 이미지
Draw Blood at the hospital.
The Test receives information and fills out the
‘Genetic Test Consent’ form.
The hospital’s staff fills out “Genetic Test Request
SD Genomics
SD Genomics receives the samples and required
SD genomics performs the requested test and
analyzes its results.
SD Genomics fills out the test report and sends it
After receiving the report, the hospital dose the
genetic counselling.

Test info

  • Whole blood (3-5 cc EDTA tube)
  • DNA 5 - 10 ug TE buffer(min. density 50 ng/uL, A260/A280 ratio: 1.65-2.0)
Sample Logistics
  • Whole Blood or DNA 15-30 ℃ room temperature(within 24 hours) 2-8 ℃ refrigerated (within 7 days)
    -30 ℃ Frozen (more than 7 days)
Required Documents Test Requirement and Consent form (provided below)
TAT Within 4-6 weeks
Report Criteria Positive : When genetic variants that are likely to cause diseases are found
Negative : When genetic variants that are likely to cause diseases are not found
Uncertain: When genetic variants are found, but is not possible to be interpreted due to current level of medicine
(When requesting institute has supplied with phenotype information)
*Consider the mode of inheritance in variant interpretation

기타 자료

1. American Society of Clinical Oncology, Practice & guidelines
2. Lindor NM et al., Concise Handbook of Familial Cancer Susceptibility Syndromes, Second Edition, Journal of the National Cancer Institute (JNCI)
3. Surveillance Epidemiology and End Results (SEER): Breast cancer, National Cancer Institute. Accessed January 2018
4. Easton DF et al., N Engl J Med 2015;372(23):2243-57